Actuate Therapeutics (ACTU US)

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The company is developing elraglusib, an ATP-competitive small molecule designed to block the function of GSK-3β, which is a master regulator of complex biological signaling cascades that lead to tumor cell survival, growth, migration, and invasion.